Browsing by Subject "cell growth"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
Item Open Access Differential p21 expression after ionizing and UVC radiation in EBV-transformed lymphoblastoid cells(2000) Moyret-Lalle, C.; Lalle P.; Pedeux, R.; Guillot, C.; Martel, S.; Magaud J.-P.; Puisieux, A.; Ozturk, M.Responses to DNA-damaging agents appear to be coordinated by p53 through transcriptional activation of critical target genes. Among them, p21WAF1 encodes a protein preventing cells from entering S phase. It is not clear whether p53-mediated response varies depending on the type of DNA damage. Here, we have decided to compare the p53-mediated response of EBV-transformed lymphoblasts to ionizing radiation and UVC irradiation. We have shown that these cells respond to ionizing radiation by a cell cycle arrest as expected. Surprisingly they failed to do so after UVC treatment. Accordingly there was no significant induction of p21 protein in UVC exposed cells despite p53 accumulation. Using isogenic EBV-transformed lymphoblastoid cells expressing E6 protein of HPV18, we have demonstrated that there was no evidence of p53-dependent cell cycle arrest after UVC irradiation. These observations suggest that the p53-mediated response to UVC, in contrast to ionizing radiation, was compromised in EBV-transformed cells and might be cell type-dependent.Item Open Access Effect of double growth factor release on cartilage tissue engineering(2013) Ertan, A.B.; Yilgor P.; Bayyurt, B.; Çalikoǧlu, A.C.; Kaspar Ç.; Kök F.N.; Kose G.T.; Hasirci V.The effects of double release of insulin-like growth factor I (IGF-I) and growth factor β1 (TGF-β1) from nanoparticles on the growth of bone marrow mesenchymal stem cells and their differentiation into cartilage cells were studied on PLGA scaffolds. The release was achieved by using nanoparticles of poly(lactic acid-co-glycolic acid) (PLGA) and poly(N-isopropylacrylamide) (PNIPAM) carrying IGF-I and TGF-β1, respectively. On tissue culture polystyrene (TCPS), TGF-β1 released from PNIPAM nanoparticles was found to have a significant effect on proliferation, while IGF-I encouraged differentiation, as shown by collagen type II deposition. The study was then conducted on macroporous (pore size 200-400μm) PLGA scaffolds. It was observed that the combination of IGF-I and TGF-β1 yielded better results in terms of collagen type II and aggrecan expression than GF-free and single GF-containing applications. It thus appears that gradual release of a combination of growth factors from nanoparticles could make a significant contribution to the quality of the engineered cartilage tissue. © 2011 John Wiley & Sons, Ltd.Item Open Access PATZ1 is a DNA damage-responsive transcription factor that inhibits p53 function(American Society for Microbiology, 2015) Keskin, N.; Deniz, E.; Eryilmaz J.; Un, M.; Batur, T.; Ersahin, T.; Atalay, R.C.; Sakaguchi, S.; Ellmeier W.; Erman, B.Insults to cellular health cause p53 protein accumulation, and loss of p53 function leads to tumorigenesis. Thus, p53 has to be tightly controlled. Here we report that the BTB/POZ domain transcription factor PATZ1 (MAZR), previously known for its transcriptional suppressor functions in T lymphocytes, is a crucial regulator of p53. The novel role of PATZ1 as an inhibitor of the p53 protein marks its gene as a proto-oncogene. PATZ1-deficient cells have reduced proliferative capacity, which we assessed by transcriptome sequencing (RNA-Seq) and real-time cell growth rate analysis. PATZ1 modifies the expression of p53 target genes associated with cell proliferation gene ontology terms. Moreover, PATZ1 regulates several genes involved in cellular adhesion and morphogenesis. Significantly, treatment with the DNA damage-inducing drug doxorubicin results in the loss of the PATZ1 transcription factor as p53 accumulates. We find that PATZ1 binds to p53 and inhibits p53-dependent transcription activation. We examine the mechanism of this functional inhibitory interaction and demonstrate that PATZ1 excludes p53 from DNA binding. This study documents PATZ1 as a novel player in the p53 pathway. © 2015, American Society for Microbiology.